Evidence map›Paper›PMID 37817661›Full record

ReviewCurrent medicinal chemistry2025

An Overview of the Pharmacological Properties of Calebin-A.

Hedieh Shamsnia, Amirreza Samanian, Ayeh Sabbagh Kashani, Danial Khayatan, Saeideh Momtaz, Thomas P Johnston, Muhammed Majeed, Tannaz Jamialahmadi, Amir Hossein Abdolghaffari, Amirhossein Sahebkar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Synergistic effects of Calebin A and docetaxel on apoptosis and migration in prostate cancer cells.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025
    Article
  5. Synergistic effects of Calebin A and docetaxel on apoptosis and migration in prostate cancer cells.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025
    Article
  6. Review
  7. Zfra Overrides WWOX in Suppressing the Progression of Neurodegeneration.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Hedieh ShamsniaDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Amirreza SamanianDepartment of Neurology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Ayeh Sabbagh KashaniDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Danial KhayatanDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Saeideh MomtazGI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Thomas P JohnstonDivision of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Muhammed MajeedSabinsa Corporation, 20 Lake Drive, East Windsor, NJ, 08520, USA.
Tannaz JamialahmadiApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Hossein AbdolghaffariDepartment of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Amirhossein SahebkarApplied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Islamic Azad University Medical Branch of Tehran · IRMashhad University of Medical Sciences · IRAcademic Center for Education, Culture and Research · IRSabin Vaccine Institute · USUniversal Scientific Education and Research Network · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The natural polyphenol, calebin-A, was recently discovered and identified as a novel phytopharmaceutical with anti-inflammatory, anti-tumor, and antiproliferative properties. Calebin-A occurs naturally in trace quantities in Curcuma longa/C cassia, commonly known as turmeric, from the Zingiberaceae family. Calebin-A is a curcumin analog or 'chemical cousin' of curcumin with a similar chemical structure. Although few research studies have been conducted on the pharmacological and therapeutic properties of calebin-A, it is a very promising molecule with a variety of pharmacological properties. Some studies have suggested that calebin-A is helpful in treating various cancers due to its inhibitory effect on cell growth and anti-inflammatory properties. Other studies have suggested that calebin-A may improve neurocognitive status associated with neurodegeneration caused by Alzheimer's disease (AD) by inhibiting the aggregation of β-amyloid. Finally, several studies have proposed that calebin-A may potentially be therapeutically beneficial in treating patients with obesity. This novel compound downregulates nuclear factor (NF)-κB-mediated processes involved with cancer, such as tumor cell invasion, proliferation, metastasis, and, most profoundly, inflammation. Moreover, calebin-A influences the activities of mitogen-activated protein kinases (MAPKs) in cancer cells. The present review identifies and discusses the pharmacological and phytochemical properties of calebin-A, as well as its therapeutic benefits and limitations, for future scientists and clinicians interested in exploring calebin-A's medicinal qualities.

Indexed as

Anti-Inflammatory AgentsAnimalsAntineoplastic AgentsAntineoplastic Agents, PhytogenicCell ProliferationCurcuminHumansNeoplasmsAnti-Inflammatory AgentsAntineoplastic AgentsAntineoplastic Agents, PhytogenicCurcuminCalebin-Acurcuminpharmacologyphytochemical.Polyphenolturmeric

Identifiers

PMID37817661
OpenAlexW4387515707

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.